Develops exosome-based therapeutic and diagnostic solutions using a clinical-driven biomarker platform that identifies disease-worsening exosomal biomarkers and therapeutic targets. Collaborates with biopharmaceutical and diagnostic companies to translate patient-derived targets into targeted therapies and treatment-management tools, shortening bench-to-bedside timelines.